512-PL-08, Poznań
- Approached×0.167 patients, 44 expected
- Agreed–7 patients approached, too few to judge
- Passed screening–3 patients screened, too few to judge
- Likely cause
- Competing trials take the same patients. The site approaches fewer patients than a site like it should, and runs other trials for the same patients. Investigators offer each patient one trial, so this study gets only a share of them. Known about this site: two or more competing trials open at the site.
- Likely cause
- Too few patients referred. The site approaches fewer patients than a site like it should, and has no clinic of its own for these patients. It depends on other doctors remembering to refer. Known about this site: relies on referrals, with no formal referral network.
- Also known
- Does not check records against the criteria before inviting patients; Two in five patients or more travel over an hour.
Agree with the investigator how patients are offered the competing trials.
An operational step with no outcome evidence; it makes the site's choice visible.
Central campaigns, recruitment vendors and referral networks. Referral routes from centres without the competing trials widen the pool.
D Evidence grade D. No quantitative evidence found in peer-reviewed comparative studies within this review. Context: in cancer care, no trial was available at the patient's centre for 55.6% of patients, which referral networks aim to address.
Add sites or countries. If several sites share the problem, add sites where competition is lower.
D Evidence grade D. No quantitative evidence on adding sites as a rescue. Diminishing returns follow from activation lag and site variability rather than from a measured effect. Context: median 0.95 participants per centre per month (IQR 0.42 to 2.60) in NIHR trials.
Central campaigns, recruitment vendors and referral networks. A formal referral network or a central campaign brings patients the site cannot reach itself.
D Evidence grade D. No quantitative evidence found in peer-reviewed comparative studies within this review. Context: in cancer care, no trial was available at the patient's centre for 55.6% of patients, which referral networks aim to address.
Opt-out contact for potential participants. Where the site holds a patient database, opt-out contact reaches more of it; needs ethics and data-protection approval.
C Evidence grade C. RR 1.39 (95% CI 1.06 to 1.84), but from a single study of 152 people; not among the high-certainty findings of the 2018 update.